Trump signs order to accelerate access to psychedelic drug treatments - Reuters

<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxOVnlGcXA1U29DNkRzcHJITEhvb0paX2lsc0EzeHdqWVBIWmphdlh3b0dmNW96bTVTaGhlU0NPQVZTRjBWUzl3Wld6a2F5Z2VWZmVfOWNZUmJEZWdLRW9LWDh5eFIyS1lPY29FQWVGTTYwb3YzUzNRMEl5ekN2b1psd1lnTS1pU0hobFJtYmhud2NzcUdJM3RWb2VFN3pFazEwRFZPMlNZM29rdmVDX0lYRQ?oc=5" target="_blank">Trump signs order to accelerate access to psychedelic drug treatments</a>&nbsp;&nbsp;<font color="#6f6f6f">Reuters</font>

President Trump is expected to sign an executive order encouraging more research into ibogaine, a psychedelic used in some countries to treat PTSD, aiming to open the door to federal funding for further research on its safety and effectiveness.

President Trump is set to order the federal government to reevaluate restrictions on ibogaine, a psychedelic drug sometimes used internationally to treat PTSD and other mental health conditions, aiming to remove significant barriers to medical research and compassionate use cases.

President Trump signed an executive order to fast-track the study of using psychedelics, including ibogaine, to treat Americans and veterans living with depression, PTSD, addiction, and other conditions, aiming to dramatically accelerate access to new medical research and treatments based on psychedelic drugs.

President Trump is expected to sign an executive order encouraging more research into ibogaine, a psychedelic used in some countries to treat PTSD, aiming to open the door to federal funding for further research on its safety and effectiveness.

President Trump signed an executive order directing the FDA to expedite the review of drugs such as ibogaine, a substance that U.S. military veteran groups have said can help treat post-traumatic stress disorder.

President Trump signed an executive order to ease restrictions on the psychedelic ibogaine, signaling the administration's willingness to further U.S. research into the drug, which is used in some countries to treat post-traumatic stress disorder.

President Donald Trump directed his administration to speed up reviews of certain psychedelic drugs, including ibogaine, ... has been embraced by combat veterans ... .

President Donald Trump signed an executive order directing his administration to expedite the review of certain psychedelic drugs, including ibogaine, for potential medical use, aiming to fast-track drug approvals and enable federal research for conditions like PTSD and severe depression.

President Trump signed an executive order to make certain psychedelic drugs more available to treat mental health conditions, such as depression and anxiety, directing $50 million in federal funds to make them more accessible, and ordered the FDA to fast track a review of such drugs as psilocybin and ibogaine.